Biognosys and Alamar seeking breakthrough in plasma biology

Biognosys from Schlieren in the canton of Zurich and the Californian company Alamar Biosciences have announced a strategic partnership. Together, the two companies intend to combine their specific competencies in biofluid-based proteomics for the benefit of biopharmaceutical and precision medicine research: Biognosys is one of the world’s leading companies in the area of mass spectrometry-based proteomics, while Alamar Biosciences is advancing precision proteomics with its NULISA assays in order to detect diseases at the earliest possible stage.

According to the press release, this partnership unites the expertise of Biognosys in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s groundbreaking immunoassays. A joint study has provided the proof of concept, while the two companies are now set to present their study findings at the Annual Meeting of the American Association for Cancer Research on April 9, 2024.

To build on this study, Biognosys and Alamar intend to continue working together both commercially and scientifically. At its state-of-the-art facility in Schlieren, Biognosys will offer NULISA assays for previously hard-to-measure cytokines, chemokines and other important disease-specific markers found in the plasma and biofluids. In addition, both companies will continue to research plasma biology with the aim of deciphering the key to biological disease mechanisms.

“Our combined efforts will pave the way for breakthroughs in plasma biology”, comments Oliver Rinner, founder and CEO of Biognosys, in the press release. “With this approach we are aiming to cover the whole dynamic range of plasma proteins”.

Biognosys is a spin-off of the Swiss Federal Institute of Technology in Zurich (ETH) with its headquarters at the Bio-Technopark Schlieren-Zurich. ce/mm